logo

English
  • Svenska
  • About us
    About us
      • This is Calliditas
      • Vision and Strategy
      • Our Pipeline
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
      • Career
  • Science
    Science
      • IgA nephropathy
      • Nefecon
      • Orphan drugs
      • Other potential indications
      • Clinical trials
        • Development program
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2020
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal control and risk management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Archive old prospectuses
      • Press releases
      • Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
      • Documentation Genkyotex tender offer
      • Capital Markets Day 2021
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Subscribe
      • Contacts
  • Contacts
    Contacts
      • Offices
      • Partnering
      • Investors
      • Media
  • Capital Markets Day 2021
  • Svenska

Media
Mikael Widell
Mikael Widell
Head of Communications and IR
E-mail: mikael.widell@calliditas.com
Mobile: +46 703 11 99 60
  • Contacts
    • Offices
    • Partnering
    • Investors
    • Media

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2021